SOPHiA GENETICS (NASDAQ:SOPH Get Rating) and Clarus Therapeutics (NASDAQ:CRXT Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.
Analyst Recommendations
This is a summary of current recommendations for SOPHiA GENETICS and Clarus Therapeutics, as reported by MarketBeat.com.
Valuation & Earnings
This table compares SOPHiA GENETICS and Clarus Therapeutics top-line revenue, earnings per share (EPS) and valuation.
Clarus Therapeutics has lower revenue, but higher earnings than SOPHiA GENETICS.
Institutional and Insider Ownership
27.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 19.5% of Clarus Therapeutics shares are owned by institutional investors. 5.3% of Clarus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares SOPHiA GENETICS and Clarus Therapeutics net margins, return on equity and return on assets.
Summary
Clarus Therapeutics beats SOPHiA GENETICS on 5 of the 9 factors compared between the two stocks.
SOPHiA GENETICS Company Profile (Get Rating)
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
Clarus Therapeutics Company Profile (Get Rating)
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
Here is the original post:
Head-To-Head Review: SOPHiA GENETICS (NASDAQ:SOPH) versus Clarus Therapeutics (NASDAQ:CRXT) - Defense World
